Literature DB >> 1540871

Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia.

C L Sawyers1, D W Golde, S Quan, S D Nimer.   

Abstract

Leukocytosis in association with malignancy has been well described, but the cause is not known. One potential explanation is production of a colony-stimulating factor by the tumor, and this has been demonstrated in vitro. The authors report two patients with lung cancer, leukocytosis, and eosinophilia. The pleural fluid of both patients contained malignant cells and biologically active granulocyte-macrophage colony-stimulating factor (GM-CSF), as demonstrated by radioimmunoassay, enzyme-linked immunosorbent assay (ELISA), and colony-forming unit-granulocyte-macrophage (CFU-GM) assay. To determine whether GM-CSF is normally detectable in pleural fluid, the authors performed assays on an additional 11 patients with pleural effusions of various origins but without peripheral blood leukocytosis and eosinophilia; only 1 patient had a detectable level of GM-CSF (i.e., greater than or equal to 0.1 ng/ml). Because GM-CSF usually is not present in pleural fluid, the authors postulate that the high levels of GM-CSF found in the pleural fluid of these two patients was produced by their tumors, and production of GM-CSF by their lung cancers likely caused the leukocytosis with eosinophilia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540871     DOI: 10.1002/1097-0142(19920315)69:6<1342::aid-cncr2820690607>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Pulmonary pleomorphic carcinoma producing granulocyte-macrophage colony-stimulating factor: report of a case.

Authors:  Toshinori Fukutomi; Mitsutomo Kohno; Yotaro Izumi; Masazumi Watanabe; Yuichiro Hayashi; Hiroaki Nomori
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 2.  Cancer-associated myeloproliferation: old association, new therapeutic target.

Authors:  Ryan A Wilcox
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

Review 3.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  TUMOUR ASSOCIATED BLOOD EOSINOPHILIA.

Authors:  Harsh Kumar; P Sivadas; R Rangarao; J R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

5.  An association between sputum eosinophilia and carcinoma of the lung: a study of 549 patients.

Authors:  P Wright; P Kelly; J Yazbeck; L Clancy; T Healy
Journal:  Ir J Med Sci       Date:  1994-11       Impact factor: 1.568

6.  Metastatic Lung Adenocarcinoma Presenting with Hypereosinophilia.

Authors:  Omar Abughanimeh; Mohammad Tahboub; Mouhanna Abu Ghanimeh
Journal:  Cureus       Date:  2018-06-22

7.  Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor.

Authors:  M Endo; K Usuki; K Kitazume; K Iwabe; Y Okuyama; A Urabe
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

8.  Highly metastatic 13762NF rat mammary adenocarcinoma cell clones stimulate bone marrow by secretion of granulocyte-macrophage colony-stimulating factor/interleukin-3 activity.

Authors:  C T McGary; M E Miele; D R Welch
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

9.  Salivary duct carcinoma with striking neutrophil-tumor cell cannibalism.

Authors:  Payam Arya; Walid E Khalbuss; Sara E Monaco; Liron Pantanowitz
Journal:  Cytojournal       Date:  2011-08-24       Impact factor: 2.091

10.  Rapidly evolving asymptomatic eosinophilia in a patient with lung adenocarcinoma causes cognitive disturbance and respiratory insufficiency: Case report.

Authors:  Cheng-Hsiang Lo; Yee-Min Jen; Wen-Chiuan Tsai; Ping-Ying Chung; Woei-Yau Kao
Journal:  Oncol Lett       Date:  2012-11-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.